# Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

> **NCT00568308** · PHASE3 · TERMINATED · sponsor: **Progen Pharmaceuticals** · enrollment: 600 (estimated)

## Conditions studied

- Cancer
- Liver Cancer
- Primary Liver Cancer
- Hepatocellular Carcinoma
- Hepatoma

## Interventions

- **DRUG:** PI-88
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00568308
- **Lead sponsor:** Progen Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 600 (ESTIMATED)
- **Why stopped:** Commercial decision to discontinue the study
- **Last updated:** 2011-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568308, "Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00568308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*